Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FerOX
- Development stage
- Preclinical
- Lead developer
- Università degli Studi di Milano
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
FerOX is an innovative nanoformulation of the anthracycline chemotherapeutic doxorubicin encapsulated within human heavy-chain ferritin (HFn) nanocages. Developed by researchers at the University of Milan, FerOX is designed to target tumor cells specifically via transferrin receptor 1 (TfR1)-mediated endocytosis, which is highly expressed on cancer cells. This targeted delivery mechanism minimizes the internalization of doxorubicin in healthy immune cells, particularly T lymphocytes, thereby preserving their proliferative capacity and maintaining host adaptive immune competence. FerOX has demonstrated preclinical efficacy in breast cancer patient-derived organoids (PDOs), patient-derived xenografts (PDX), and syngeneic mouse models of triple-negative breast cancer, showing improved tumor delivery, reduced cardiotoxicity, and enhanced immune system preservation compared to free doxorubicin.
- Other names
- doxorubicin-loaded ferritin nanocagesferritin-encapsulated doxorubicinferritin-nanocaged doxorubicinHFn-DOX
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on FerOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FerOX.